Relationship Between Hematological Toxicities During Maintenance Treatment and During Chemotherapy Before Maintenance Treatment in Patients With Platinum-sensitive Relapsed Ovarian Cancer

• Published in: Anticancer research Vol. 43; no. 8; pp. 3653 - 3658
• Main Authors: Matsuoka, Hirofumi, Nakamura, Keiichiro, Yorimitsu, Masae, Ogawa, Mariko, Kanemori, Miho, Sueoka, Kotaro, Kozai, Ayumi, Nakamura, Hiroko, Haruma, Tomoko, Shiroyama, Yuko, Hayata, Yuu, Sugii, Hirokazu, Ueda, Akiko, Kurihara, Shuichi, Urayama, Saiko, Shimizu, Miyuki, Masuyama, Hisashi
• Format: Journal Article
• Language: English
• Published: Greece International Institute of Anticancer Research 01.08.2023
• Subjects: Anemia; Anemia - chemically induced; Antineoplastic Combined Chemotherapy Protocols - adverse effects; Cancer; Carcinoma, Ovarian Epithelial - drug therapy; Chemotherapy; Female; Hematology; Humans; Maintenance; Maintenance Chemotherapy; Neoplasm Recurrence, Local; Ovarian cancer; Ovarian Neoplasms - drug therapy; Patients; Platinum; Progression-Free Survival; Toxicity; chemotherapy before maintenance treatment; platinum-sensitive relapsed ovarian cancer; Maintenance treatment; anemia
• ISSN: 0250-7005; 1791-7530
• DOI: 10.21873/anticanres.16546

To determine if maintenance treatment can be performed effectively and safely in patients with platinum-sensitive relapsed ovarian cancer. We carried out a multi-center study to investigate progression-free survival (PFS) and adverse events (AEs) in 229 patients receiving maintenance treatment for platinum-sensitive relapsed ovarian cancer. The median PFS in the 229 patients with maintenance treatment was 14.0 months (95% confidence interval=10.3-17.6 months). The hematological toxicities included ≥grade 3 anemia in 33.2% of cases. Anemia during maintenance treatment was significantly more common than anemia during chemotherapy given before maintenance treatment (p<0.001). Anemia during chemotherapy prior to maintenance treatment significantly increased the risk of anemia during maintenance treatment, compared with other clinical features (p<0.001). Maintenance treatment can be performed safely and effectively in patients with platinum-sensitive relapsed ovarian cancer. Anemia during chemotherapy given before maintenance treatment significantly increased the risk of developing anemia during maintenance treatment in patients with platinum-sensitive relapsed ovarian cancer.